Ecolab, Inc. ECL is scheduled to report fourth-quarter 2024 results on Feb. 11, 2025, before the opening bell.
In the last reported quarter, the company’s earnings per share (EPS) of $1.83 surpassed the Zacks Consensus Estimate by 0.6%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 0.79%, on average.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
Let’s see how things have shaped up for Ecolab prior to this announcement.
Global Industrial
The Global Industrial segment, comprising the Water, Food & Beverage, Paper and Downstream units, witnessed a sales uptick in the third quarter of 2024. Per management, the Global Industrial segment’s growth was driven by accelerating Water sales growth. Water’s performance was led by strong growth in downstream and light water. We are optimistic about the continued strength in Ecolab’s Water business and expect it to have significantly boosted the company’s fourth-quarter revenues as well.
In November 2024, Ecolab announced the acquisition of Barclay Water Management. The acquisition enhances Ecolab's water treatment capabilities, expands its customer base, and creates cross-selling opportunities. It strengthens Ecolab’s portfolio in key industries, supports sustainable solutions, and aligns with its growth and margin expansion goals.
Per management, third-quarter Food & Beverage sales reflected good new business wins. Paper sales were stable compared to the year-ago quarter’s performance. This is likely to have continued in the to-be-reported quarter as well.
The Zacks Consensus Estimate for the fourth-quarter Global Industrial segment revenues is currently pegged at $2 billion, indicating an uptick of 7.9% from the year-ago quarter’s reported figure.
Global Institutional & Specialty
Ecolab’s Global Institutional & Specialty segment recorded strong growth in the last reported quarter, courtesy of the company’s performance in the Institutional and Specialty divisions. Per the third-quarterearnings call management commented on the Institutional and Specialty business’ strong performance and margin expansion. The segment delivered strong organic sales growth on top of last year's double-digit gains.This trend is likely to have continued in the to-be-reported quarter as well.
Per management, the main driver of robust performance in the Institutional and Specialty segment is that the company is helping its customers with labor automation. Ecolab’s chemical solutions, machine programs and digital technologies are helping its restaurant and hotel customers serve more guests better while using less labor. Additionally, Ecolab’s segmental revenues for the to-be-reported quarter are also likely to have benefited from new business wins.
The Zacks Consensus Estimate for the fourth-quarter Global Institutional & Specialty segment revenues is currently pegged at $1.36 billion, implying an uptick of 7.2% from the year-ago quarter’s reported figure.
Other Factors at Work
In the third-quarter Pest Elimination’s organic sales (a component of Ecolab’s broader Other segment) witnessed growth of 9%. Sustained strong demand for Pest Elimination in commercial businesses is likely to have driven the segment’s revenues in the to-be-reported quarter as well.
Per management, during the third quarter, robust performance was seen in specific high-tech and clean-tech subsegments, particularly data center cooling, microelectronics, and water circularity solutions. These areas benefited from Ecolab’s innovative technologies and enhanced value pricing strategies, despite broader economic challenges in some industrial markets.
The company’s continued investments in digital technologies and customer penetration opportunities, particularly under the One Ecolab initiative, might have further bolstered growth in the to-be-reported quarter.
Ecolab Inc. Price and EPS Surprise
Ecolab Inc. price-eps-surprise | Ecolab Inc. Quote
The Estimate Picture
For fourth-quarter 2024, the Zacks Consensus Estimate of $3.97 billion for total revenues implies an improvement of 0.9% from the prior-year quarter’s reported figure.
The consensus estimate for EPS is pegged at $1.77, implying an improvement of 14.2% from the prior-year period’s reported number.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. This is not the case here, as you can see below.
Earnings ESP: Ecolab has an Earnings ESP of -3.36%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are some medical stocks worth considering as these have the right combination of elements to post earnings beat this reporting cycle.
Globus Medical GMED has an Earnings ESP of +3.95% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The company expects to release its fourth-quarter and full year 2024 results on Feb. 20. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%. The Zacks Consensus Estimate for earnings indicates an improvement of 26.67% from the year-ago reported figure.
Merit Medical Systems MMSI has an Earnings ESP of +2.62% and a Zacks Rank #2 at present. The company is slated to release its fourth-quarter and full year 2024 results on Feb. 25.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.42%. The Zacks Consensus Estimate for earnings indicates an improvement of 2.47% from the year-ago quarter’s figure.
Masimo MASI has an Earnings ESP of +4.05% and a Zacks Rank of 2 at present.
The company expects to release its fourth-quarter and full year 2024 results on Feb. 25. MASI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.1%.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpEcolab Inc. (ECL) : Free Stock Analysis Report
Masimo Corporation (MASI) : Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
Globus Medical, Inc. (GMED) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
